Lenacapavir injection lowers HIV risk by 96%
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
healthday7h
Incidence of HIV Lower With Twice-Yearly Subcutaneous Lenacapavir
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...
How Gilead Is Driving Global Health Equity And Innovation
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
clinicaltrialsarena5d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
Interesting Engineering on MSN1d
From chronic to curable: Twice-yearly shot shows near-total HIV eradication
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
India Today on MSN10h
New injection reduces risk of HIV infection by 96%: All about it
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
Six-Month HIV Prevention Shot Achieves 99% Efficacy in Major Study
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
fingerlakes11d
Twice-Yearly HIV Shot Could Revolutionize Prevention, But Access Remains Uneven
A new HIV prevention drug, lenacapavir, has shown 100% effectiveness in women and near-perfect results in men during trials.
Gilead announces PURPOSE 2 trial data published in NEJM
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...
Hosted on MSN4d
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...